CHINA – Perpetual Medicine, a Shanghai, China- and Boston, MA-based computational peptide therapeutics company, raised $8M in Seed funding.
The round was led by Chengwei Capital.The company intends to use the funds to advance its integrated computational design and synthesis platform for peptide drug discovery. Perpetual Medicines is a computational peptide therapeutics company that aims to build a peptide drug discovery engine. Its platform combines the predictive computational physics methods and AI technologies with synthetic chemistry to discover the peptide chemical space. The platform is designed to address previously undruggable targets, accelerate discovery and enhance the quality of peptide drug candidates. The company also announced key appointments to its leadership team, including Kerry L. Blanchard, MD, PhD, Co-founder, CEO, Ved Srivastava, PhD, CTO, and Xiang Ye, PhD, CSO.01/12/2023
